Oestrogen receptor-a (ER) is the defining and driving transcription factor in the majority of breast cancers and its target genes dictate cell growth and endocrine response, yet genomic understanding of ER function has been restricted to model systems [1] [2] [3] .
Here we map genome-wide ER-binding events, by chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq), in primary breast cancers from patients with different clinical outcomes and in distant ER-positive metastases. We find that drug-resistant cancers still recruit ER to the chromatin, but that ER binding is a dynamic process, with the acquisition of unique ER-binding regions in tumours from patients that are likely to relapse. The acquired ER regulatory regions associated with poor clinical outcome observed in primary tumours reveal gene signatures that predict clinical outcome in ER-positive disease exclusively. We find that the differential ER-binding programme observed in tumours from patients with poor outcome is not due to the selection of a rare subpopulation of cells, but is due to the FOXA1-mediated reprogramming of ER binding on a rapid timescale. The parallel redistribution of ER and FOXA1 binding events in drug-resistant cellular contexts is supported by histological co-expression of ER and FOXA1 in metastatic samples. By establishing transcription-factor mapping in primary tumour material, we show that there is plasticity in ER-binding capacity, with distinct combinations of cis-regulatory elements linked with the different clinical outcomes.
Recent technological advances have allowed mapping of ERbinding events, with the goal of discovering the cis-regulatory elements and factors involved in mediating ER binding and transcription. Several genome-wide maps of ER in breast cancer cell-line models exist 1-3 , all showing that most ER-binding events occur at distal cisregulatory elements. Forkhead motifs are enriched within the regions bound by ER binding and multiple studies have identified the forkhead protein FOXA1 as an important pioneer factor for ER-chromatin interactions [4] [5] [6] . However, the ER mapping studies have been restricted to breast cancer cell lines, mostly the MCF-7 cell line. We sought to interrogate ER-binding events, for the first time, in primary frozen breast cancer samples, to determine if ER binding is dynamic and if specific cis-regulatory elements can distinguish tumours from patients with distinct clinical outcomes.
ER ChIP-seq was performed in eight ER 1 , progesterone receptor (PR) 1 , HER2 2 primary breast tumours, representative of tumours from patients with better prognosis 7 , a conclusion supported by the available long-term clinical follow-up ( Supplementary Fig. 1 ). Also included were seven primary breast tumours from patients with a poor outcome (ER 1 PR 2 HER2 2 or ER 1 PR 1 HER 1 ), because PR 2 or HER2 1 tumours are more likely to be aggressive 8, 9 . As expected, the poor outcome patients who had long-term clinical follow-up died of breast cancer ( Supplementary Fig. 1 ). Furthermore, three ER 1 distant metastatic samples from women with breast cancer were included. The metastatic locations and sample preparation can be found in Supplementary Fig. 1 . As a control, we included two breast cancer samples that were ER 2 (ER-a negative), but expressed high transcript levels of ER-b.
ER ChIP-seq was conducted and ER-binding peaks were called using two different algorithms, MACS 10 and SWEMBL (http://www. ebi.ac.uk/,swilder/SWEMBL/), to minimize peak caller bias. The number of sequencing reads and ER-binding events for each tumour is shown in Supplementary Fig. 2 . ER binding could be mapped in all tumours, but total peak intensity and the number of identified binding events differed. Three tumours were split into two sections and ER ChIP-seq was conducted on the separate sections. We found very good concordance when comparing different sections of the same tumour (R 2 5 0.954) suggesting that tumour heterogeneity did not substantially influence the ER-binding signal obtained from a sample (Supplementary Fig. 3 ).
We initially assessed whether a conserved set of breast cancer ERbinding events could be identified. We found a core set of 484 ERbinding events that were identified in at least 75% of all the tumours, but not in either of the ER 2 tumours (Fig. 1a ). Peak calling details can be found in Supplementary Fig. 4 . An example of a core ER-binding event is shown in Fig. 1b . This demonstrates that ER binding to chromatin still occurs even in tumours that are unlikely to respond to antioestrogen therapies, implying that drug resistance is not due to loss of ER binding to DNA. The average ER-binding signal intensity was highest in the metastatic samples and lowest in patients with good outcome tumours, a phenomenon observed both within the 484 core ER-binding regions ( Fig. 1c ) and globally ( Supplementary Fig. 4 ). These data indicate that there is an acquisition of binding signal intensity in tumours that progress towards a poorer prognosis and ultimately metastasize. The only DNA motif found to be enriched in the core ERbinding events was an oestrogen responsive element (ERE) (Fig. 1d ). The genes near (within 20 kilobases (kb): an optimal window between ER-binding events and target genes 11 ) the 484 core ER-binding events exhibited elevated expression in the ER 1 tumours used for ChIP-seq, as compared to all other genes (data not shown) and were higher in ER 1 tumours relative to ER 2 tumours in nine independent data sets ( Supplementary Fig. 5 ). The genes are provided in Supplementary Fig. 6 and include classic ER target genes such as TFF1, GREB1 and RARA. A gene predictor was generated based on genes near the core ER-binding events. Patients were stratified and the tumours with the highest 'risk index' had a poor clinical outcome when compared to the tumours with the lowest 'risk index' (Fig. 1e shows the results based on one study 12 and additional data sets are shown in Supplementary Fig. 6 ; only ER 1 patients were considered). These conserved cis-regulatory elements and their putative target genes may be the elements that contribute to tumorigenesis and are maintained regardless of the clinical outcome of the breast cancer patient. In contrast to the primary breast cancers and metastases, we mapped ER binding in three normal human mammary glands and two normal human liver samples and found limited numbers of ER-binding events, with almost no concordance in ER binding between individuals (data not shown).
We sought to determine if differential ER-binding events could discriminate the patients with good outcome (ER 1 PR 1 HER2 2 tumours), from patients with poor outcome or metastases (we described the combined set as poor/met tumours). After normalization of the data to account for global differences in ER binding, differential binding analysis (DBA) was used to identify ER-binding events that were statistically enriched in one category or the other. This resulted in a set of ER-binding events that could discriminate between the two groups when using principal component analysis Figure 2 | ER-binding profiles can discriminate between tumours from patients with different clinical outcomes. a, Principal component analysis (44% of total variance) of the 1,791 ER-binding events that can discriminate between the patients with good outcome tumours and those with poor/met tumours. Included are the replicates from three tumours, which are highlighted. b, Box plot representing distribution of normalized read counts in differential ER-binding events that are statistically enriched in either the patients with good outcome tumours (599 ER-binding events) or the patients with poor outcome tumours and metastases (Mets) (1, 192 ER-binding events). The samples were pre-normalized. **P , 1 3 10 210 . P values were calculated using the Wilcoxon rank sum test. c, Enriched motifs in the poor/met and the good outcome ERbinding events. d, Genes within 20 kb of the differentially bound ER-binding events were used to generate a gene predictor. Tumours were stratified according to expression of this gene signature and the top one third and bottom one third of tumours were compared. Results from one data set are shown 12 and additional data sets are provided in Supplementary Fig. 12 . 
Figure 1 | A subset of ER-binding events is conserved in primary breast
tumours and distant metastases. a, Heat map showing binding peak intensity of 484 core ER-binding events that are common to primary breast tumours and distant metastases. The window represents 65 kb regions from the centre of the binding events. b, Example of an ER-binding event at the RARA locus, which is present in all primary ER 1 breast tumours and metastases, but not the ER 2 tumours. c, Normalized average signal intensity of all core ER-binding events. Also included are the ER 2 tumours. d, Motif analysis revealed the enrichment of EREs. e, Genes within 20 kb of the core ER-binding events were used to generate a gene predictor that was tested in independent data sets for predictive value. Tumours were stratified according to expression of this gene signature and the top one third and bottom one third of tumours were compared. Results from one data set are shown 12 and additional data sets are provided in Supplementary Fig. 6 .
RESEARCH LETTER ( Fig. 2a ). In total, DBA revealed 1,192 genomic regions that had significantly more ER binding in the poor/met group compared to the good outcome patients (Fig. 2b) , and 599 ER binding regions with more ER binding in the good outcome patients when compared to the poor/met patients (Fig. 2b) . The clustering of the tumours on the basis of the 1,791 differential ER-binding events can be visualized in Supplementary Fig. 7 . These findings suggest that there are specific and re-occurring cis-regulatory elements that are occupied by ER in breast cancers, but that these are different in tumours that respond to treatment versus those that relapse and metastasize. Analysis of enriched DNA motifs identified the presence of ERE and FOXA1 motifs in the differential poor outcome ER-binding events and ERE motifs in the good outcome ER-binding events (Fig. 2c ). Correlation of the poor outcome ER-binding events with known processes revealed an association with endocrine resistance and luminal B status ( Supplementary  Fig. 8 ).
To investigate if the genes near the differential ER-binding events were potentially functional in breast cancer, we analysed genes within a 20 kb window around the 1,192 poor/met and 599 good outcome ER-binding events. Using a training set, we generated a gene expression predictor for each of the good and poor outcome gene lists. The probability calculation and comparisons between the good and poor outcome genes is shown in Supplementary Figs 9 and 10 . Within the poor outcome gene list was the oncogene ERBB2 (all genes are shown in Supplementary Fig. 11 ). As expected, genes in the poor outcome predictor were preferentially upregulated in poor outcome patients, whereas those in the good outcome predictor were preferentially downregulated ( Supplementary  Fig. 10 ). We next tested the predictors in an independent large cohort of breast cancer patients 12 , only considering ER 1 tumours. Using distant-metastasis-free survival as an endpoint, both gene sets predicted outcome (P 5 3 3 10 25 for good and 3 3 10 28 for poor outcome genes) in this data set 12 and with the expected opposite directionality (Fig. 2d ). The gene predictors were associated with survival in additional data sets ( Supplementary Fig. 12 ) and were largely independent of histopathological factors ( Supplementary Fig. 13 ). We tested 1,000 randomizations from the entire list of genes and determined that the probability that a random set of genes would yield an equally robust predictor of clinical outcome was P 5 0.004. Furthermore, the good and poor gene predictors had no predictive power in four cohorts of ER 2 patients ( Supplementary Fig. 14) . This suggests that the increased ER binding at distinct cis-regulatory elements is functionally and biologically relevant, resulting in altered gene expression profiles that contribute to differences in drug response and overall survival.
To validate the findings made in the tumours, we explored the possibility that ER-binding events were acquired in cell-line models of endocrine resistance. ER binding was mapped by ChIP-seq in three commonly used tamoxifen-responsive, ER 1 breast cancer cell lines (MCF-7, T-47D and ZR75-1), and two tamoxifen-resistant, ER 1 breast cancer cell lines, namely a tamoxifen-resistant MCF-7 derivative (TAM-R) 13 and BT-474 cells that are ER 1 and contain the ERBB2 amplification (ER 1 HER2 1 ). Similar to BT474 cells, TAM-R cells have increased ERBB2 protein levels 13 and both represent cellular systems in which increased growth factor signalling results in endocrine resistance. For all five cell lines, ER ChIP-seq was performed in at least duplicate, in asynchronous cells to recapitulate the situation observed in primary tumours ( Supplementary Fig. 2 ).
Almost 7,000 (6,920) ER-binding events were identified in all replicates of all cell lines ( Fig. 3a and Supplementary Fig. 15 ). Almost all (98.9%) of the core ER-binding events that occurred in most primary tumours (Fig. 1a ) overlapped with the cell-line core ER-binding events. DBA identified 8,188 ER-binding events with significantly stronger binding affinity in the tamoxifen-resistant cell lines, and 5,713 ERbinding events that were stronger in the tamoxifen-responsive cell lines (Fig. 3a) . Examples of differentially bound regions are shown in Fig. 3b . Using the differential ER-binding events, the cell-line classification can be visualized by principal component analysis ( Fig. 3c ) and hierarchical clustering (Fig. 3d ). Enriched motif analysis revealed ERE and FOXA1 motifs in regions showing increased ER binding in tamoxifen-resistant cell lines (Fig. 3e) , which are the same motifs observed in the poor outcome ER-binding events in primary tumours (Fig. 2c) . GATA motifs were enriched in ER-binding events depleted during acquisition of drug resistance (Fig. 3e) , possibly due to competition between FOXA1 and GATA3, another prominent breast cancer transcription factor.
We hypothesized that the ER-binding events induced in the tamoxifenresistant breast cancer cell lines would be the same regions that were enriched in the poor/met clinical samples. However, 79.8% of the 1,192 ER binding events enriched in the poor/met samples (from Fig. 2b ) overlap with ER-binding events in wild-type MCF-7 cells, suggesting that the cell-line models are closer to the tumours and metastases from poor outcome patients. In support of this, the 599 good outcome ERbinding events observed in primary tumours (Fig. 2b) overlap poorly with the ER binding observed in MCF-7 cells (30.2% versus 79.8% for the poor outcome). Interestingly, MCF-7 cells (plus T-47D and ZR75-1 cells) were derived from the pleural effusion of metastatic breast cancer patients, but were established before tamoxifen use in the clinic. We propose that MCF-7, ZR75-1 and T-47D cell lines possess an intermediate ER-binding profile with the acquisition of additional ERbinding regions required for resistance to anti-oestrogen treatment. 
LETTER RESEARCH
The differences in ER binding between responsive and resistant contexts may be due to selection and expansion of a resistant subpopulation, or may be due to reprogramming of ER binding following specific stimuli. Growth factor pathways have long been implicated in modulating endocrine response 14, 15 and have been shown to influence ER-binding potential and gene expression profiles 14 . We identified various stimuli (EGF, IL-6, TNF-a and IGF-I) shown to induce increased cellular invasion and drug resistance and treated asynchronous MCF-7 cells with control or the cocktail of mitogens for 90 min (Fig. 4a ). Duplicate ER ChIP-seq replicates were performed (Supplementary Fig. 2) .
Differential binding analysis identified 6,089 ER-binding regions that were differentially enriched ($4 fold change difference, false discovery rate (FDR) ,0.1) following a 90 min treatment with the cocktail. These mitogen-induced ER-binding differences could be visualized using principal component analysis (Fig. 4b) . Because FOXA1 is a pioneer factor required for ER-chromatin interactions 4 and FOXA1 motifs were enriched in both the mitogen-induced ERbinding events ( Supplementary Fig. 16 ) and the tumours from the poor outcome patients (Fig. 2c) , we assessed whether the rapid, reprogrammed ER binding occurred at regions pre-determined by FOXA1. We repeated the mitogen treatment, but mapped FOXA1 binding by ChIP-seq and found that ,25% of the reprogrammed ER-binding events (1, 515) occur at regions that are already bound by FOXA1, before mitogen treatment (Fig. 4c) . A substantial proportion (37.6%) of the other reprogrammed ER-binding events occur at regions where FOXA1 binding is also induced by mitogens. As such, ,53% of mitogen-induced ER-binding events occur at regions pre-bound by FOXA1 or at regions that also acquire FOXA1 binding (Fig. 4c ), a level of concordance that mirrors the ,50% overlap observed in wild-type cells 6 .
To determine if FOXA1 expression was present in ER 1 distant metastases, we obtained 24 metastatic samples (bone, brain and liver) from ER 1 breast cancer patients and performed immunohistochemistry for ER and FOXA1 (Fig. 4d ). We found that ,87% of the metastases retained ER expression and that FOXA1 expression occurred in ,95% of the metastases (Fig. 4e) . Importantly, the concordance between ER and FOXA1 was high (R 2 5 0.585), regardless of the site of metastasis. Therefore, the co-expression of ER and FOXA1 in distant metastases supports our conclusions that FOXA1 mediates ER reprogramming.
By mapping ER binding in clinical samples, we provide a first glimpse of the primary regulatory regions that contribute to differences within ER 1 breast cancers, rather than secondary events such as gene expression profiles. Our findings suggest that there is plasticity in ER binding, with distinct ER-binding profiles associated with clinical outcome. These differential ER-binding profiles seem to be mediated by FOXA1. A remaining question is what dictates differential FOXA1 and subsequently ER binding. Possibilities include changes in the genomic landscape, alterations in co-factor levels or changes in FOXA1 structure and function, potentially by post-translational modifications. By establishing transcription factor mapping in primary samples, we find that differential ER-binding patterns govern gene expression programs and are associated with clinical outcome in ER 1 cancer.
METHODS SUMMARY
MCF-7, ZR75-1, T-47D and BT-474 human cell lines were obtained from the American type culture collection (ATCC) and grown in the relevant media. TAM-R cells 13 were a gift from I. Hutcheson and R. Nicholson (Cardiff). The ER 1 breast cancer tumours were obtained from the Nottingham Tenovus primary breast cancer series, Addenbrooke's Hospital and Imperial College Healthcare NHS Trust, with appropriate ethical approval from the repositories. The malignant pericardial effusion and the two distant metastases were obtained from Imperial College Healthcare NHS Trust. For ChIP in the tumours and metastases, the frozen sample was cut into smaller pieces before ChIP, which was then performed as previously described 16 . For the malignant pericardial effusion, epithelial cells were first enriched using Dynabeads conjugated with Epcam 17 . For ChIPs from cell-line material, proliferating cells were cross-linked and processed for ChIP as previously described 16 . The antibodies used were anti-ER (sc-543) from Santa Cruz Biotechnologies and anti-FOXA1 (ab5089) from Abcam. Sequences generated by the Illumina Genome Analyzer were processed by the Illumina analysispipelineversion1.6.1,andalignedtotheHumanReferenceGenome(assembly hg18, NCBI build 36.1, March 2008) using BWA version 0.5.5 (ref. 18 ). Differential binding analysis was performed using the DiffBind package 19 . For immunohistochemical analyses, ER staining was conducted using the 6F11/2 mouse monoclonal antibody (Novocastra, Leica Microsystems) and FOXA1 staining was conducted using a rabbit polyclonal antibody (ab23738) from Abcam. An Allred scoring system was used to assess staining accounting for both staining intensity and the proportion of cells stained. 
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METHODS
Cell culture. MCF-7, ZR75-1, T-47D and BT-474 human cell lines were obtained from the American type culture collection (ATCC). MCF-7 cells were grown in DMEM containing 10% heat-inactivated FBS, 2 mM L-glutamine, 50 U ml 21 penicillin and 50 mg ml 21 streptomycin. ZR75-1, T-47D and BT-474 cells were grown in RPMI containing 10% heat-inactivated FBS, 2 mM L-glutamine, 50 U ml 21 penicillin and 50 mg ml 21 streptomycin. To validate the cell lines, samples were genotyped by the Health Protection Agency (http://www.hpa. org.uk) (MCF-7, ZR75-1, T-47D) or by in-house genotyping (BT-474). TAM-R cells 13 were obtained from I. Hutcheson and R. Nicholson (Cardiff) and were maintained in phenol-red-free DMEM containing 5% charcoal dextran-treated FBS, 2 mM L-glutamine, 50 U ml 21 penicillin and 50 mg ml 21 streptomycin and 10 nM 4-hydroxytamoxifen.
Primary tumour material. The ER 1 breast cancer tumours were obtained from the Nottingham Tenovus primary breast cancer series, Addenbrooke's Hospital and Imperial College Healthcare NHS Trust, with appropriate ethical approval from the repositories. The malignant pericardial effusion and the two distant metastases were obtained from Imperial College Healthcare NHS Trust. See Supplementary Fig. 2 for clinical details.
Chromatin immunoprecipitations. The antibodies used were anti-ER (sc-543) from Santa Cruz Biotechnologies and anti-FOXA1 (ab5089) from Abcam. For ChIP in the tumours and metastases, the frozen sample was cut into smaller pieces and thawed in 1% (final concentration) formaldehyde for 20 min at room temperature (20 uC) . The reaction was quenched by adding 0.1 volume of 2 M glycine for 10 min. The sample was disaggregated by Dounce homogenization and processed according to standard ChIP procedures 16 . The DNA was subsequently amplified as previously described 16 . For the malignant pericardial effusion, epithelial cells were first enriched using Dynabeads conjugated with Epcam 17 .
For ChIPs from cell-line material, proliferating cells were cross-linked and processed for ChIP as previously described 16 . For the TAM-R cells, ER ChIP-seq was performed on cells grown in DMEM containing 10% FBS and 10 nM tamoxifen for 24 h. For the cocktail experiments, cells were treated with 100 ng ml 21 IGF-1, 100 ng ml 21 EGF, 1 ng ml 21 TNF-a and 10 ng ml 21 Figs 4A and 15 ), significantly differentially bound sites were identified by first counting the number of reads in the ChIP samples overlapping each identified peak (subtracting the number of overlapping reads from the corresponding input sample). Differential analysis was performed using the edgeR package 20 . Normalization factors were computed using the TMM technique, after which tagwise dispersions were calculated and subjected to an exact test 20 .
Resulting P values were subjected to Benjamini-Hochberg multiple testing correction to derive FDRs; only sites differentially bound with a FDR , 0.1 (cell line samples) or a P value ,0.01 were considered for further analysis. The differential binding analysis and related plots were performed using the DiffBind package 19 .
Heat-map generation. To generate the heat maps of the raw ChIP-seq data, ERbinding peaks in the different samples were used as targets to centre each window. Each window was divided into 100 bins of 100 bp in size. An enrichment value was assigned to each bin, counting the number of sequencing reads in that bin normalized to 10,000,000 sequencing reads, after subtracting the number of normalized input reads per bin. Motif analysis. For analysis of enriched DNA motifs, Weeder was used, with the default settings 21 .
Distant-metastasis-free-survival analysis. First, we computed for each gene in the given ER-binding list (ER-core-binding events, good outcome ER binding, poor/met ER binding) a P value and statistic from a univariate Cox regression, individually in nine independent data sets 12, [22] [23] [24] [25] [26] [27] [28] [29] . This was done to ascertain if the observed directionalities of association between gene expression and outcome were consistent with the predictions from the differential ER-binding events. Histograms of P values over all cohorts clearly confirmed the association of the ER-binding events with distant-metastasis-free survival (DMFS; Supplementary  Fig. 9 ). Moreover, genes more bound in poor prognosis and metastatic tumours were generally more highly expressed in poor prognosis tumours ( Supplementary  Fig. 10 ). We adopted a two-step strategy to first learn from the pool of genes in a given ER-binding list, a subset with patterns of gene expression that are associated with DMFS in a training set, and second to then validate this predictor in completely independent data. We used the ER 1 breast cancer samples from two independent data sets as training sets 22, 23 , re-normalized the gene expression profiles to mean zero and unit variance and applied a singular value decomposition to the resulting reduced expression matrices. For each of the top 10 eigenvectors (principal components) we correlated their profiles across samples to DMFS using a Cox regression, and next identified DMFS-associated eigenvectors, which were also highly correlated (or anticorrelated) between the two training sets. Thus, our algorithm is similar to the supervised principal components algorithm (SPCA) previously described 30 , but differs in that we extend this procedure to two training sets. We consistently identified DMFS-associated eigenvectors that were also highly correlated between the two training sets. A prognostic predictor was constructed by averaging the DMFS-associated eigenvectors from each training set. The predictor was subsequently tested in seven independent ER 1 breast cancer cohorts 12, [24] [25] [26] [27] [28] [29] . Specifically, for each sample we computed the Pearson correlation of the predictor with the sample expression profile over the genes that could be mapped. The resulting correlation can be viewed as the risk index. In each cohort this risk index was then evaluated in a Cox regression to test ability to predict DMFS. The data shown in Fig. 1e and Fig. 2d is derived from the Loi data set 12 , but the additional data sets are provided in Supplementary Fig. 6 and 12 .
The Sweave document describing all analyses can be found at http:// c3315341.r41.cf0.rackcdn.com/Data.tar.gz. Immunohistochemisty. Immunohistochemistry of full-face sections was performed using a BondMax Autoimmunostainer (Leica Microsystems). ER staining was conducted using the 6F11/2 mouse monoclonal antibody (Novocastra, Leica Microsystems) at 1 in 70 and antigen retrieval was performed by heating with pH 6 citrate buffer for 30 min. FOXA1 staining was conducted using a rabbit polyclonal antibody (ab23738) from Abcam, at 1 in 800 with antigen retrieval performed by heating with pH 6 citrate buffer for 20 min. Bound primary antibody was detected using a BOND polymer detection kit (Leica) and developed with 3-39diaminobenzidine (DAB). The degree of staining was assessed by a pathologist (H.R.A.) using a standard light microscope. An Allred scoring system was used to assess staining accounting for both staining intensity (0 5 none, 1 5 weak,
